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Functional Plasticity of Central TRPV1 Receptors
in Brainstem Dorsal Vagal Complex Circuits of
Streptozotocin-Treated Hyperglycemic Mice
Andrea Zsombok,1,2 Muthu D. Bhaskaran,1 Hong Gao,2 Andrei V. Derbenev,1,2 and Bret N. Smith1
1

Department of Physiology, University of Kentucky College of Medicine, Lexington, Kentucky 40536, and 2Department of Physiology, Tulane University,
Health Sciences Center, New Orleans, Louisiana 70112

Emerging data indicate that central neurons participate in diabetic processes by modulating autonomic output from neurons in the
dorsal motor nucleus of the vagus (DMV). We tested the hypothesis that synaptic modulation by transient receptor potential vanilloid
type 1 (TRPV1) receptors is reduced in the DMV in slices from a murine model of type 1 diabetes. The TRPV1 agonist capsaicin robustly
enhanced glutamate release onto DMV neurons by acting at preterminal receptors in slices from intact mice, but failed to do so in slices
from diabetic mice. TRPV1 receptor protein expression in the vagal complex was unaltered. Brief insulin preapplication restored TRPV1dependent modulation of glutamate release in a PKC- and PI3K-dependent manner. The restorative effect of insulin was prevented by
brefeldin A, suggesting that insulin induced TRPV1 receptor trafficking to the terminal membrane. Central vagal circuits critical to the
autonomic regulation of metabolism undergo insulin-dependent synaptic plasticity involving TRPV1 receptor modulation in diabetic
mice after several days of chronic hyperglycemia.

Introduction
Type-1 diabetes (T1D) is an autoimmune disease resulting from
destruction of insulin-secreting pancreatic islet ␤ cells (Tisch and
McDevitt, 1996). Diabetes has been handled mainly as a peripheral metabolic disease, but accumulating evidence indicates that
the brain plays a critical role in regulating glucose homeostasis via
activity of neurons controlling autonomic functions (Oomura,
1980; Undeland et al., 1998; Schwartz and Porte, 2005).
Along with key hypothalamic nuclei, the brainstem dorsal vagal complex (DVC) plays an important role in the autonomic
control of feeding, regulation of pancreas and liver metabolism,
and other autonomic functions. Neurons in the DVC are able to
respond to both hypoglycemia and hyperglycemia (Ferreira et al.,
2001; Balfour et al., 2006; Balfour and Trapp, 2007), consistent
with their critical role in whole-body energy homeostasis. Acute
hyperglycemia or increased glucose concentration in the DVC
tends to inhibit vagal output, whereas chronic hyperglycemia
causes vagal nerve activity to increase (Laury et al., 1991; Ahrén et
al., 1996). Chronically altered vagal function is common in diabetic patients (see Zsombok and Smith, 2009). Hepatic glucose
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production is altered in diabetes, and this substantially involves
central autonomic circuits controlling vagal output to the liver
(Pocai et al., 2005a,b; Lam et al., 2010). Intact hepatic vagal output is required for a significant portion of the inhibition of gluconeogenesis following central or peripheral administration of
insulin, suggesting that increased circulating insulin levels affect
neural circuits required to restrain hepatic gluconeogenesis (Pocai et
al., 2005b).
The role of transient receptor potential vanilloid type 1
(TRPV1) in diabetes was recently demonstrated (Suri and Szallasi, 2008) and suggests that events controlling T1D development
and glucose dysregulation are not only immunological, but also
neurological (Tsui et al., 2007). Several reports, mainly associated
with diabetic neuropathy, indicate that peripheral TRPV1 receptor activity and protein levels are altered in diabetic models.
In primary afferent neurons, TRPV1 expression is upregulated
(Rashid et al., 2003), and significant increases in capsaicin sensitivity and proton-activated inward currents were observed in animals with streptozotocin (STZ)-induced diabetes (Hong and
Wiley, 2005). In sensory neuron homogenates, total TRPV1 protein was decreased, but increased protein levels were detected on
plasma membranes (Hong and Wiley, 2005). Insulin enhanced
TRPV1-mediated currents in heterologous expression systems
and cultured primary sensory neurons (Van Buren et al., 2005).
These observations suggest that deficiencies in insulin signaling
and/or enhanced glucose-dependent mechanisms contribute to
altered TRPV1 function and complications of diabetes.
Centrally, activity of TRPV1 potently modulates synaptic input to motor neurons of the dorsal motor nucleus of the vagus
(DMV), which ultimately regulates visceral function (Derbenev
et al., 2006). TRPV1 activity in the DMV alters, for example,
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gastrointestinal function, but central attributes of TRPV1 function
associated with diabetes have not been identified. Here, we tested the
hypothesis that TRPV1 is functionally downregulated in an insulindependent fashion in putative preganglionic parasympathetic motor
neurons of the DMV in a mouse model of T1D, and we determined
the cellular mechanism underlying the effect of insulin on TRPV1mediated synaptic modulation in these neurons.

Materials and Methods
Animals. Male CD-1 mice (5– 8 weeks old; Harlan) were used for these
experiments. Animals were housed in a vivarium under 12 h light, 12 h
dark cycle with food and water available ad libitum. The University of
Kentucky and Tulane University Animal Care and Use Committees approved all animal procedures.
Streptozotocin injection. Mice were fasted overnight (6 –10 h) and then
injected intraperitoneally with STZ (200 mg/kg; Alexis Biochemicals)
dissolved in 0.1 M citrate buffer, at pH 4.5. Control animals received
citrate buffer injections. Body weight and blood glucose levels (One
Touch Ultra) were monitored before injection and then daily afterward.
Mice with blood glucose levels ⬎300 mg/dl (16.6 mM) for at least 3 d were
considered to be hyperglycemic and were used for further experiments.
Brainstem slice preparation. Acute brainstem slices containing the
DMV were prepared from male control and STZ-treated hyperglycemic
CD-1 mice. Animals were deeply anesthetized by halothane inhalation to
effect (Sigma) and then decapitated. The brain was removed and immersed in an ice-cold (0 – 4°C) artificial CSF (aCSF) bubbled with 95%
O2–5% CO2. The composition of aCSF was (in mM): 124 NaCl, 3 KCl, 26
NaHCO3, 1.4 NaH2PO4, 11 glucose, 1.3 CaCl2, and 1.3 MgCl2, pH 7.3–
7.4. Transverse brainstem slices (i.e., coronal plane; 300 m) containing
the DMV were cut with a vibratome. The slices were transferred to a
holding chamber, which contained oxygenated aCSF at 34 –36°C for 1 h
before being transferred to a recording chamber mounted on the fixed
stage of an upright microscope (Olympus BX51WI; or Nikon FN1).
Whole-cell patch-clamp recordings. Whole-cell patch-clamp recordings
were performed at 34 –36°C under visual control on an upright, fixed
stage microscope equipped with infrared illumination and differential
interference contrast optics (IR-DIC). For whole-cell patch-clamp recordings, electrodes (2–5 M⍀) were filled with a solution containing the
following (in mM): 130 Cs ⫹-gluconate, 1 NaCl, 5 EGTA, 10 HEPES, 1
MgCl2, 1 CaCl2, 3 CsOH, 2–3 Mg-ATP, pH 7.3–7.4, adjusted with 5 M
CsOH. EPSCs were examined at a holding potential of ⫺60 or ⫺70 mV.
Electrophysiological signals were recorded using an Axoclamp 700B amplifier (Molecular Devices), low-pass filtered at 2 kHz, and stored to a
computer using a Digidata 1440A digitizer and pClamp 10 software (Molecular Devices). Synaptic currents were analyzed offline using pClamp
10 and MiniAnalysis 6.0.3. (Synaptosoft).
Drug application. All recordings were performed with tetrodotoxin
(TTX; 1 M) in the aCSF solution to block action potentials and monitor
mEPSCs. The TRPV1 receptor agonist capsaicin (1 M; Tocris Bioscience), the TRPV1 antagonist capsazepine (CPZ, 10 M) or the TRPV1
antagonist 5⬘-iodoresiniferatoxin (5⬘-iRFT, 1 M; Tocris Bioscience), the
TRPV4 agonist 4␣-phorbol 12,13-didecanoate (4-␣-PDD, 1 M; Alexis
Biochemicals), and the Golgi disrupting agent brefeldin A (5 M, Sigma)
were dissolved in ethanol and diluted in aCSF (final concentration of
ethanol ⬍0.01% by volume). A PKC activator, phorbol 12-myristate
13-acetate (PMA, 1–3 M, Tocris Bioscience); a PKC inhibitor, GF
109203X (BIM, 500 nM or 2 M; Tocris Bioscience); and a PI3K inhibitor,
wortmannin (3 M; Sigma), were dissolved in DMSO and diluted in
aCSF (final DMSO concentration ⬍0.01%). Insulin (1 M, Novolin R,
Novo Nordisk) was diluted in aCSF.
Statistical analysis. The effect of agonists and antagonists on mEPSC
frequency and amplitude were analyzed within individual cells using the
Kolmogorov–Smirnov test by comparing 2 min epochs before and after
drug application (⬎200 events each condition). The effects of agonists
and antagonists across the neuron groups were analyzed using a paired
two-tailed Student’s t test, and effects between different groups were
analyzed using one-way ANOVA. Number of replicates (i.e., n) is neurons recorded, with numbers of mice also indicated for each experiment;
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probability values over the 95% confidence level (p ⬍ 0.05) were considered significant; averages obtained across neurons are expressed as the
mean ⫾ SEM.
Western blot detection and quantification. Transverse (i.e., coronal)
sections of the brainstem (400 M) were made from control and STZtreated hyperglycemic mice using a vibratome, and the caudal DVC was
microdissected to include the DMV and nucleus tractus solitarius. The
samples were homogenized at 4°C in lysis buffer (0.5 M HEPES, 3 M NaCl,
1 M MgCl2, 0.5 M EDTA, 0.1 M DTT, 10% SDS, 10% deoxycholate, and
0.3% Triton X-100) and centrifuged at 13,000 rpm at 4°C for 10 min. The
supernatant was collected, leaving the pellet behind. Proteins were quantified using Bradford protein assay. Each lane was loaded with 15 g of
protein in 7.5% Tris䡠HCl polyacrylamide gels and electrophoresed at 110
V for 60 –90 min. Proteins were then transferred at 200 mA for 1 h to
polyvinylidene difluoride membranes for Western blot analysis. Membranes were rinsed in PBS and blocked in 1:1 Odyssey blocking buffer/
PBS (Odyssey, Li-COR Biosciences) for 1 h at room temperature.
Membranes were then either incubated 1 h at room temperature or overnight at 4°C, with an anti-rat VR1 N terminus (1:2500) (Neuromics) and
an anti-mouse ␣-actin (1:1000) primary polyclonal antibodies (Sigma)
in 1:1 Odyssey blocking buffer/PBS/0.1% Tween 20. Following four 5
min washes (PBS ⫹ 0.1% Tween 20), membranes were incubated with
fluorescence-conjugated goat anti-rabbit IRDye-680 and goat antirabbit IRDye-800 secondary antibodies (IgG; 1:5000 Odyssey) in Odyssey blocking buffer/PBS/0.1% Tween 20 and 0.01% SDS for 1 h, followed
by four 5 min washes. After a final 10 min PBS wash, the membranes were
dried and blots were scanned by a densitometer (Odyssey model 9120,
Li-COR Biosciences) to quantify band density. Background density was
subtracted from the VR1 band density and normalized to ␣-actin, which
was used as the loading control. Western blots were analyzed using
single-factor ANOVA. Results are reported as the mean ⫾ SEM; significance was set at p ⬍ 0.05 for all statistical measures.

Results
TRPV1 activity is altered in STZ-treated hyperglycemic mice
Injection of STZ (200 mg/kg; i.p.) resulted in hyperglycemia
within 3 d (⬎300 mg/dl; 16.6 mM), which was maintained for up
to 1 week. The mean blood glucose level in STZ-treated mice
measured 4 d after the injection (528.1 ⫾ 13.4 mg/dl, n ⫽ 53) was
significantly higher than in control mice (178.7 ⫾ 3.4 mg/dl, n ⫽
40; p ⬍ 0.05). Animals were used for experiments 3–7 d after STZ
treatment.
Synaptic input to motor neurons of the DMV potently regulates
autonomic output to the viscera. The frequency and amplitude of
action potential-independent miniature EPSCs (mEPSCs) in the
DMV was examined in the presence of TTX (1 M) in slices from
control and STZ-treated hyperglycemic animals, maintained in normal artificial CSF (aCSF). To analyze the effect of 3–7 d of continuous hyperglycemia and insulin deficiency on TRPV1 receptor
activity in the DMV, the TRPV1 agonist capsaicin was applied while
recording synaptic currents in DMV neurons, voltage clamped at
⫺60 or ⫺70 mV. Similar to effects in rats (Derbenev et al., 2006),
bath application of capsaicin (1 M) significantly and consistently
increased the frequency of mEPSCs in DMV neurons from control
mice (Fig. 1A), and this occurred regardless of the anatomical position of the neuron within the nucleus. The effect of capsaicin was
observed within 2 min of the drug reaching the slice and was maximal by 5 min. Under control conditions, the average mEPSC frequency was 11.0 ⫾ 1.9 Hz (range 3.4 –20.6 Hz; n ⫽ 10 cells from 5
mice). After application of capsaicin (1 M), the mean frequency of
mEPSCs increased to 17.1 ⫾ 3.8 Hz (range 8.1– 42.9 Hz, 69 ⫾ 16%
increase; n ⫽ 10; p ⬍ 0.05; Fig. 1A,C,E). There was no significant
change in mEPSC amplitude after capsaicin application, confirming
that the agonist acted at presynaptic glutamatergic terminals to enhance glutamate release (Derbenev et al., 2006). The average amplitude in neurons from control mice was 16.2 ⫾ 1.8 pA (range 8 –27
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pA) and 16.9 ⫾ 2.3 pA (range 8 –30 pA; p ⬎
0.05) after application of capsaicin. In DMV
cells in slices from control mice, mEPSC frequency, but not amplitude, was significantly
enhanced by capsaicin, similar to results in
rats (Derbenev et al., 2006).
Unlike responses in slices from intact
mice, application of capsaicin did not increase the frequency of mEPSCs in DMV
neurons from STZ-treated, hyperglycemic mice (Fig. 1 B, D,E). Under control recording conditions (i.e., normal aCSF
with TTX), the mean mEPSC frequency
was 14.4 ⫾ 3.5 Hz (range 2.0 –35.7 Hz;
n ⫽ 12 from 6 mice). After application of
capsaicin, the average frequency of mEPSCs was unchanged (16.2 ⫾ 4.0 Hz; 15 ⫾
11% change; range 2.3– 43.8 Hz; p ⬎
0.05). The amplitude of mEPSCs in neurons from STZ-treated hyperglycemic
mice was 15.8 ⫾ 1.1 pA (range 11–23 pA) Figure 1. TRPV1 activation increases mEPSC frequency in control, but not in STZ-treated hyperglycemic mice. A, Sample of
continuous recording of mEPSC frequency observed in DMV neuron from a control mouse in the presence of tetrodotoxin (TTX; 1
and 17.9 ⫾ 1.7 pA after application of capM). Upper trace, control (i.e., TTX only). Bath application of capsaicin (1 M) increased mEPSC frequency (lower trace). B, Similar
saicin (range 12–33 pA; p ⬎ 0.05). The recording of mEPSCs in a DMV neuron from a STZ-treated hyperglycemic mouse (upper trace). Bath application of capsaicin had
selective effect of capsaicin on mEPSC fre- little effect on mEPSCs. C, D, Cumulative event probability plots of interevent interval distribution in 2 min recordings from DMV
quency in control mice was significantly cells in slices from control (C) and STZ-treated (D) mice. E, Combined data showing the effect of capsaicin in control and STZ-treated
greater than in STZ-treated mice (p ⬍ mice. Capsaicin increased mEPSC frequency in neurons from control animals but failed to increase mEPSC frequency in
neurons from STZ-treated hyperglycemic animals. Asterisk indicates significance (p ⬍ 0.05). The number of replicates is
0.05; Fig. 1).
The background mEPSC frequency shown above each bar.
was significantly higher in slices from
ference in TRPV1 protein expression between the two groups
STZ-treated, hyperglycemic mice than in controls (p ⬍ 0.01; Fig.
(n ⫽ 8; p ⬎ 0.05; Fig. 3), suggesting that the altered response to
2 A–C). The average mEPSC frequency was 8.9 ⫾ 0.9 Hz (range
TRPV1 activation was not due to diminished TRPV1 expression
1.4 –24.2 Hz; n ⫽ 35 from 16 mice) in control animals and 13.7 ⫾
in STZ-treated hyperglycemic mice.
1.3 Hz (range 2.7–35.7 Hz; n ⫽ 44 from 18 mice) in STZ-treated
hyperglycemic animals (Fig. 2 A). To determine whether the increased frequency—and therefore the lack of agonist effect—in
Incubation with insulin restores the TRPV1 activity
STZ-treated mice was due to tonic endogenous TRPV1 activity,
Slices from STZ-treated, hyperglycemic mice were preincubated
the effect on mEPSC frequency of a TRPV1 receptor antagonist,
with insulin (1 M; 30 ⫾ 10 min) to determine the effect of
5⬘-iRFT, was examined. Application of 5⬘-iRFT (1 M) did not
insulin restoration on TRPV1 function (Fig. 4). When comparing
result in a significant change in the frequency of mEPSCs in STZcells from insulin-treated slices with cells from control slices,
treated hyperglycemic or control animals (Fig. 2 D). In neurons
there was a small but nonsignificant effect of insulin alone on
from STZ-treated, hyperglycemic mice, the average frequency
mEPSC frequency in slices from STZ-treated hyperglycemic mice
was 14.8 ⫾ 2.1 (range 10.3–22.9 Hz) before application of 5-iRFT
(13.7 ⫾ 1.3 Hz; n ⫽ 44 versus 8.8 ⫾ 2.1 Hz; n ⫽ 10 with insulin;
and 12.4 ⫾ 4.6 Hz (range 7.5–26.3 Hz; n ⫽ 5; p ⬎ 0.05) after
p ⬎ 0.05; unpaired t test). However, preincubation with insulin
antagonist application. Another TRPV1 antagonist, capsazepine,
restored the effect of capsaicin on mEPSC frequency. The average
was also without effect in any of three cells. Application of 5⬘mEPSC frequency in slices from STZ-treated hyperglycemic mice
iRFT (1 M) alone did not alter mEPSC frequency in control mice
in the continuous presence of insulin for several minutes was
(n ⫽ 5; p ⬎ 0.05; Fig. 2 D), but prevented the increase in mEPSC
8.8 ⫾ 2.1 Hz (range 0.6 –22.2 Hz; n ⫽ 10 from 6 mice). In the
frequency upon capsaicin application.
continued presence of insulin, bath application of capsaicin (1
M) significantly increased mEPSC frequency in each cell tested
TRPV1 receptor protein expression
to 14.6 ⫾ 3.7 Hz (82 ⫾ 12% increase; n ⫽ 10; range 1.1–33.2 Hz;
was not altered in STZ-treated hyperglycemic mice
p ⬍ 0.05). The magnitude of the capsaicin-induced increase was
Since the ability of TRPV1 receptor activation to enhance glutasignificantly greater than in neurons from STZ-treated hyperglymate release in the DMV was diminished in slices from STZcemic animals without insulin incubation (p ⬍ 0.05; Fig. 4 B),
treated hyperglycemic mice, the relationship between altered
and was similar to the capsaicin-induced increase seen in control
TRPV1 receptor activity and changes in receptor protein expresmice (i.e., 69 ⫾ 16%; p ⬎ 0.05). These data indicate that acute
sion in the DVC was investigated. The DVC was microdissected
exposure to insulin can restore TRPV1 receptor functionality in
from slices of control and STZ-treated hyperglycemic mice.
DVC neurons from STZ-treated mice.
Western blot analyses were made to compare TRPV1 levels in
control and STZ-treated hyperglycemic mice. A discrete band at
Insulin modulates TRPV1 receptor activity in a PI3K/
95 kDa, corresponding to the molecular weight of the TRPV1
PKC-dependent manner
receptor, was identified by Western blot, consistent with previous
Blocking PKC
TRPV1 receptors are known to be sensitive to PKC modulation
studies using this antibody (Stein et al., 2006; Bhaskaran and
(Van Buren et al., 2005). Insulin binds insulin receptors (IRs) in
Smith, 2010). Western blot analysis identified no significant dif-
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tion of the slices with PMA restored the
effect of capsaicin (Fig. 5). In slices from
STZ-treated hyperglycemic mice in the
presence of PMA, the average mEPSC frequency was 14.3 ⫾ 4.4 Hz (range 2.9 – 48.3
Hz) before capsaicin application and was
increased to 24.7 ⫾ 9 Hz by the addition
of the TRPV1 agonist in each cell tested
(84 ⫾ 17% increase; range 4.9 –57.1 Hz;
n ⫽ 10 from 6 mice; p ⬍ 0.05; Fig. 5).
The PI3K pathway
To verify that the restoration of the response
to capsaicin observed after incubation with
insulin was due to increased PI3K activity,
we examined the effect of the PI3K inhibitor
wortmannin on neurons from STZ-treated
hyperglycemic mice. Preincubation of slices
with wortmannin (3 M) plus insulin (1
M) diminished the ability of insulin to restore sensitivity to capsaicin (1 M) versus
the restored effect in the presence of insulin
alone. In the presence of wortmannin plus
Figure 2. Miniature EPSC frequency was significantly higher in DMV neurons from STZ-treated hyperglycemic mice compared insulin, the average mEPSC frequency beto controls. A, Mean group differences in mEPSC frequency in normal and STZ-treated mice. Number of neurons in each group is fore was 14.5 ⫾ 3.0 Hz (range 1.4 –34.4 Hz)
indicated in parentheses. Asterisk indicates significance between the groups (p ⬍ 0.05). B, Sample recordings of mEPSCs observed and was 19.1 ⫾ 3.9 Hz after addition of capat holding potential of ⫺60 mV in neurons from control (upper trace) and STZ-treated hyperglycemic (lower trace) mice. C,
saicin (range 1.1– 40.1 Hz; n ⫽ 10 from 4
Combined data showing the distribution of mEPSC frequencies for cells from control and STZ-treated hyperglycemic mice. D,
Application of the TRPV1 antagonist 5=-iRFT did not significantly change mEPSC frequency in neurons from control or STZ-treated mice; p ⬎ 0.05; Fig. 5). In slices from control
animals, indicating that latent TRPV1 activity was not responsible for the increased mEPSC frequency in treated mice. The number mice, wortmannin incubation before capsaicin application did not influence the effect
of replicates is shown above each bar.
of capsaicin. Capsaicin increased mEPSC
frequency by 81 ⫾ 30% in the presence of
the brain and, via insulin receptor substrate 2, a functional comwortmannin alone in controls, similar to the increase in the absence
ponent of the IR, activates PI3K and elevates the level of PKC in
of wortmannin (p ⬎ 0.05). TRPV1 receptor-mediated modulation
cultured primary sensory neurons (Van Buren et al., 2005). To
of glutamate release does not require PI3K activity in intact or STZdetermine whether insulin acted via a PKC-dependent mechanism
treated hyperglycemic animals, but PI3K is required for the full
to restore the TRPV1 receptor activity in the DMV in hyperglycemic
insulin-dependent restoration of capsaicin’s effect in slices from
mice, the effect of a selective and potent PKC inhibitor, bisindolylSTZ-treated, hyperglycemic mice.
maleimide I (BIM) on the capsaicin-induced increase in mEPSC
frequency was tested in slices from STZ-treated hyperglycemic mice.
Insulin-dependent TRPV1 receptor translocation
Slices were preincubated with insulin (1 M) and BIM (500 nM-2
Insulin has been shown to induce rapid delivery of functional
M) for 30 min and mEPSCs were recorded before and after capsaTRPV1 receptors to the plasma membrane in cultured DRG cells
icin (1 M) application. The average frequency before capsaicin apand in heterologous expression systems (Van Buren et al., 2005).
plication was 10.0 ⫾ 2.1 Hz (range 2.1–25.0 Hz, n ⫽ 9 from 4 mice).
Since total TRPV1 protein expression (i.e., assessed by Western analApplication of capsaicin failed to increase mEPSCs frequency in the
ysis) was similar between the two groups, we reasoned that the
presence of insulin plus the PKC inhibitor (10.8 ⫾ 2.3 Hz; range
insulin-dependent reinstatement of TRPV1 receptor function in the
2.3–25.9; 8 ⫾ 4% change; p ⬎ 0.05). Inhibition of PKC activity with
DMV involved receptor translocation to synaptic terminal memBIM prevented the insulin-induced restoration of the capsaicin efbrane. To test this hypothesis, brefeldin A was preapplied to slices for
fect in slices from STZ-treated animals (Fig. 5).
10 –55 min to disrupt the Golgi apparatus and interfere with recepWe also tested the effect of BIM on slices from control anitor trafficking, followed by the addition of insulin for 30 min. The
mals, and observed that in the presence of 500 nM BIM, capsaicin
average mEPSC frequency in the presence of brefeldin A (5 M) plus
failed to cause a significant increase in the mEPSC frequency,
insulin (1 M) was 15.5 ⫾ 3.1 Hz (range 2.2–32.9 Hz) and was
suggesting that the effect of capsaicin also required PKC activity
18.2 ⫾ 2.9 Hz (range 2.2–33.3 Hz) after addition of capsaicin (1 M;
under normal conditions. In this set of control mice, the average
n ⫽ 11 from 5 mice; p ⬎ 0.05). Preincubation of the slices from
mEPSC frequency was 11.6 ⫾ 2.6 Hz (range 1.9 –21.5 Hz) and
STZ-treated, hyperglycemic animals with brefeldin A prevented the
was 12.7 ⫾ 2.4 Hz (range 2.3–21.2 Hz) after application of capinsulin-dependent reinstatement of the TRPV1-mediated enhanced
saicin (1 M) in the presence of BIM (n ⫽ 7 from 3 mice; p ⬎
glutamate release (Fig. 5).
0.05).
PKC activation
To verify the involvement of PKC in the reinstatement of TRPV1
function by insulin, we preincubated the slices from STZ-treated
animals with a PKC activator, phorbol 12-myristate 13-acetate
(PMA; 3 M; 20 min). Similar to the effect of insulin, preincuba-

TRPV4 sensitivity was not altered after STZ treatment
To assess the possibility that TRP receptors were nonspecifically
altered in slices from STZ-treated mice, the function of a close
TRP family member, TRPV4, was assessed. The effect of the selective TRPV4 agonist 4-␣PDD was examined in control and
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Figure 3. TRPV1 expression levels were not different in STZ-treated hyperglycemic mice. A,
Western blot showing a band at 95 Kd, consistent with TRPV1 expression in the vagal complex
from control and STZ-treated hyperglycemic mice. Actin was used as a loading control. B,
Western blot densitometry analysis detected no significant difference in TRPV1 protein levels
between control and STZ-treated mice. The number of replicates is shown above each bar.

Figure 5. Insulin modulates TRPV1 receptor activity in a PI3 kinase- and PKC-dependent
manner. Mean group changes in mEPSC frequency showing the effect of capsaicin under different conditions. Significant differences between effects of capsaicin on mEPSC frequency in DMV
neurons from control mice versus those from STZ-treated hyperglycemic mice are illustrated
(see Fig. 1). The restorative effect of insulin is also shown (see Fig. 4). Activation of PKC by the
addition of PMA restored the effect of capsaicin in slices from STZ-treated hyperglycemic mice.
Inhibition of PKC or PI3 kinase activity with BIM or wortmannin, respectively, diminished the
ability of insulin to restore the capsaicin-induced mEPSC frequency increase in STZ-treated,
hyperglycemic mice. Brefeldin A, which disrupts Golgi function and receptor trafficking, also
prevented the restorative effect of insulin on TRPV1-modulated glutamate release. Asterisks
indicate significant mEPSC frequency differences between neurons tested in the presence of
insulin alone versus in insulin plus kinase or Golgi inhibitors (p ⬍ 0.05). The number of replicates is shown above each bar.

Figure 4. The TRPV1 receptor-mediated increase in glutamate release was reinstated in
STZ-treated hyperglycemic mice in the presence of exogenously applied insulin. A, Sample
recordings of mEPSCs observed at holding potential at ⫺60 mV in the presence of insulin (1 M;
upper trace). Preincubation of the slices with insulin for 20 min restored the capsaicin-induced
increase in mEPSC frequency (bottom trace). B, Cumulative event probability plots of interevent
interval distribution in recordings from STZ-treated mice in the presence of insulin (control)
and insulin ⫹ capsaicin. C, Mean group changes in mEPSC frequency showing the effect of
capsaicin in STZ-treated hyperglycemic mice in the absence and presence of insulin. The number
of replicates is shown in parentheses above each bar; the asterisk indicates significant difference
in the effect of capsaicin in the presence of insulin (p ⬍ 0.05).

STZ-treated hyperglycemic animals. Application of 4-␣PDD (1
M) resulted in a significant increase in mEPSC frequency in
slices from both control and STZ-treated hyperglycemic mice
(p ⬍ 0.05). The effect of 4-␣PDD was observed within 2 min of
the drug reaching the slice and was maximal by 5 min. The frequency of mEPSCs was increased 50 ⫾ 12% by 4-␣PDD in DMV
neurons from control animals (10.7 ⫾ 1.8 Hz; range 1.4 –15.2 Hz,
control; 16.3 ⫾ 3 Hz, range 2–24.8 Hz, 4-␣PDD; n ⫽ 7; p ⬍ 0.05;
Fig. 6 B). Similarly, application of 4-␣PDD increased mEPSC frequency by 68 ⫾ 14% in DMV neurons from STZ-treated hyperglycemic animals (from 12.1 ⫾ 3.1 Hz; range 1.1–25.6 Hz,
control; 19.3 ⫾ 5.1 Hz; range 2.2– 41.9 Hz, 4-␣PDD; n ⫽ 8; p ⬍
0.05). There was no significant difference in the magnitude of the

Figure 6. TRPV4 receptor activity was not altered in STZ-treated hyperglycemic mice. A,
Sample trace showing mEPSCs in DMV neuron from an STZ-treated hyperglycemic mouse in
control aCSF (upper trace) and in the presence of 4␣PDD (1 M; lower trace), a selective TRPV4
receptor agonist. B, Mean group changes in mEPSC frequency showing similar magnitude of
4␣PDD-induced increase in control and STZ-treated hyperglycemic mice. Bath application of
4␣PDD significantly increased mEPSC frequency in both control and STZ-treated hyperglycemic
mice (p ⬍ 0.05). The number of replicates is shown above each bar.

effect between the two groups, suggesting that TRPV4 function
remained intact in STZ-treated hyperglycemic animals.

Discussion
Elevated glucose can acutely alter cellular function in the vagal
complex (Ferreira et al., 2001; Balfour et al., 2006), and chronically altered excitability in neurons is often associated with compensatory, plastic changes in receptor function. Here, the
TRPV1-mediated enhancement of glutamate release in the DMV
was suppressed after 3–7 d of frank hyperglycemia due to STZinduced insulin depletion, even when glucose concentration in
the slices was normalized and identical between groups of record-
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ings. Prolonged hyperglycemia can induce vagally stimulated insulin release (Laury et al., 1991) and can result in tonically altered
vagus nerve activity (Ahrén et al., 1996), independent of insulin
availability. Hyperglycemia is associated with increased
GABAergic tone in the DVC (Ferreira et al., 2001). Chronic hyperglycemia may alter synaptic balance sufficiently to contribute
to the functional receptor changes observed here, including a
possibly compensatory increase in glutamatergic contribution.
Diminished TRPV1-mediated glutamate release is consistent
with reduced synaptic excitation and therefore decreased vagal
motor tone, which would be expected to contribute to diabetic gastroparesis accompanying vagal dysregulation (Saltzman and McCallum, 1983). Moreover, since vagal activity tends to inhibit hepatic
gluconeogenesis, altered excitability of DMV neurons would be expected to contribute to hepatic glucose dysregulation.
In addition to chronic hyperglycemia, the absence of insulin
signaling may also have contributed to an internalization of
TRPV1 receptors in synaptic terminals. Consistent with this hypothesis, preapplication of insulin or a PKC activator reinstated
the effects of capsaicin. Acute blockade of PKC in slices from
normal animals prevented capsaicin’s effect, whereas disruption
of PKC activity or of receptor trafficking prevented the insulindependent reinstatement of TRPV1 to enhance glutamate release
in STZ-treated hyperglycemic animals. Although a number of
factors might be responsible for the diminished TRPV1 function,
chronically elevated glucose levels and/or diminished insulin levels seem likely to be the most salient features of the effect. Restoring TRPV1 function by insulin or PKC modulation may
represent an avenue for restoring DMV neuron activity and normalizing parasympathetic output in diabetic patients.
The role of the CNS in diabetes
Type-1 diabetes is generally conceptualized as an autoimmune,
metabolic disorder due to ␤-cell loss. However, a growing body of
evidence suggests that the brain plays an important role in the
regulation of energy balance and glucose metabolism (Sandoval
et al., 2008; Zsombok and Smith, 2009). It is generally accepted
that there is a specific central network receiving afferent information regarding the status of peripheral metabolism via hormonal
signaling, which is relevant to energy/glucose balance and regulation (Pocai et al., 2005b; Perez-Tilve et al., 2006; Sandoval et al.,
2008). This central network, which includes the DVC, connects
the brain with peripheral metabolic processes in the viscera, including hepatic gluconeogenesis, gastrointestinal motility, digestion, and pancreatic exocrine function (Barber and Burks, 1987;
Ferreira et al., 2001; Pocai et al., 2005b). These observations support the hypothesis that disruption of the normal physiological
balance between sympathetic and parasympathetic output due to
dysregulated central synaptic function is a key factor promoting
development of the metabolic syndrome.
The autonomic network is centered in hypothalamus and
brainstem circuits, which are robustly interconnected. Roles for
hypothalamic and brainstem neurons in energy regulation have
been demonstrated (Sandoval et al., 2008). Administration of
insulin to the paraventricular nucleus (PVN) induced suppression in hepatic gluconeogenesis, which was mediated by the vagus (Pocai et al., 2005b). Specific alteration of glutamate activity
in the DVC also affects hepatic glucose production (Lam et al.,
2010). The DVC plays a critical role in the autonomic parasympathetic control of energy homeostasis via the vagus nerve, and
modulation of neural circuits in this area profoundly alters digestive and metabolic processes.
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The TRPV1 receptor in the brain
The importance of TRPV1 receptor in peripheral sensory systems
during diabetes has been established (Razavi et al., 2006; Suri and
Szallasi, 2008), but the role of central TRPV1 receptors is not yet
as clear. The existence of TRPV1, a nonselective cation channel,
has been demonstrated in the brain (Mezey et al., 2000; Cristino
et al., 2006), including in DVC where it can be activated by capsaicin or anandamide (Derbenev et al., 2006), resulting in enhanced glutamate release. Notably, anandamide also binds
cannabinoid receptors in the DVC (Derbenev et al., 2004), activation of which, if unopposed by TRPV1 binding, would tend to
inhibit glutamate release. The expression of TRPV1 is altered
peripherally in several diseases affecting metabolism, including
diabetes. Activation of PKC induces TRPV1 activity in the absence of another agonist and potentiates the response of TRPV1
to capsaicin (Premkumar and Ahern, 2000). Stimulating PKC
with PMA reinstated the TRPV1-mediated enhancement of
mEPSC frequency in STZ-treated hyperglycemic mice. This is
consistent with the observation that application of BIM, a PKC
inhibitor, prevented the capsaicin-induced enhancement of
mEPSC frequency in control slices, which further supports the
involvement of PKC in TRPV1 activation and enhancement of
glutamate release centrally.
The present results in central motor circuits demonstrate that
TRPV1 receptor activity is diminished in the brainstem of STZtreated, hyperglycemic mice in an insulin-dependent fashion.
However, a reduction in total TRPV1 protein expression levels
was not detected in the DVC of T1D mice and the TRPV1mediated response was reinstated by PKC upregulation, suggesting that the receptors were present but functionally unavailable.
In the periphery, insulin traffics glucose transporters to the membrane to allow cellular glucose utilization (Kahn and Cushman,
1985). In addition to sensitizing TRPV1 receptors, PKC can also
traffic the receptor to the plasma membrane in cultured cells
(Van Buren et al., 2005). Application of brefeldin A disrupts receptor trafficking in the vagal complex (Browning et al., 2004)
and disrupting receptor trafficking with brefeldin A prevented
the insulin-induced reinstatement of the capsaicin effect. Similarly, insulin potentiates TRPV1 function in Xenopus oocytes and
neuroblastoma cells (Lilja et al., 2007) in a PI3K- and PKCdependent manner, effects that were due to increased protein
expression, increased receptor sensitivity, and membrane translocation (Morenilla-Palao et al., 2004). Our findings are consistent with the hypothesis that insulin potentiates TRPV1 receptor
function on glutamatergic synaptic terminals in the DMV by
translocating them to the synaptic terminal membrane in a PI3Kand PKC-dependent manner. Unlike TRPV1, the functional
expression of TRPV4, which has also been demonstrated to be
located centrally (Liedtke et al., 2000; Güler et al., 2002), was not
altered, indicating that a nonspecific alteration in TRP family
expression or function did not occur.
Insulin in the brain
Insulin crosses the blood– brain barrier via a saturable transport
mechanism (Margolis and Altszuler, 1967; Banks, 2004) and is
transported into the brainstem and hypothalamus over twice as
rapidly as into whole brain (Banks, 2004), which highlights the
importance of these brain areas in glucose metabolism. The brain
is insulin independent with respect to glucose utilization, but
neuronal insulin receptors are expressed in the DVC (Pardini et
al., 2006), and centrally acting insulin regulates peripheral energy
homeostasis and glucose metabolism (Obici et al., 2002; Schwartz
and Porte, 2005). Here, we show that application of insulin onto
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slices from STZ-treated hyperglycemic animals rapidly restores
the capsaicin-induced increase in mEPSC frequency, suggesting a
partial reconstitution by insulin of normal synaptic control of
vagal output in these animals. The effect of insulin on reinstatement of TRPV1-dependent effects in preganglionic vagal neurons that regulate visceral function represents a potentially novel,
insulin-dependent means of regulating metabolism centrally.
The connection between TRPV1 and insulin
The mEPSC frequency was significantly higher in the brainstem
of STZ-treated hyperglycemic mice than in controls, suggesting
tonically increased glutamate release in these animals. We tested
the hypothesis that the increased mEPSC frequency was due to
tonic TRPV1 activation, which could obscure the effects of
TRPV1 agonists. However, significant TRPV1 antagonistinduced changes in mEPSC frequency were not detected, indicating that the enhanced mEPSC frequency was unlikely to be due to
increased tonic TRPV1 activity. In the hippocampus, insulin enhances NMDA receptor function, increasing channel opening
probability by enhancing the number of NMDA receptors in the
cell membrane and NR1 subunit surface expression (Skeberdis et
al., 2001), but insulin-induced alteration of glutamate receptor
function was not overt in the DMV. The basis for the tonically
elevated glutamate release in the DMV of STZ-treated hyperglycemic mice remains a subject for future investigation.
Modulation of central TRPV1 function suggests altered DMV
output in STZ-treated, hyperglycemic mice, which may contribute to altered glucose metabolism by decreasing the ability of
TRPV1 binding to alter excitability of DMV neurons that regulate
liver, pancreas, or gastrointestinal viscera. This would be consistent with a dysregulation of hepatic gluconeogenesis, and gastrointestinal responses might include diminished digestive reflexes,
depending on the type of postganglionic circuit targeted by the
DMV neuron. Whether insulin sensitivity of this circuit is altered
in type 2 diabetes is not known, but development of insulin resistance in the DVC could similarly contribute to the development of diabetic symptoms. The observations here support an
emerging and significant role of central TRPV1 in regulating and
responding to glucose and insulin levels in patients with diabetes,
as well as indicating a novel cellular mechanism of insulindependent regulation of synaptic modulation in neurons.
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Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A,
Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid
receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central
nervous system of the rat and human. Proc Natl Acad Sci U S A
97:3655–3660.
Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel A
(2004) Regulated exocytosis contributes to protein kinase C potentiation
of vanilloid receptor activity. J Biol Chem 279:25665–25672.
Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin
signaling is required for inhibition of glucose production. Nat Med
8:1376 –1382.
Oomura Y (1980) Input-output organization of the hypothalamus relating
to food intake behavior. In: Handbook of the hypothalamus, Vol 2, Physiology of the hypothalamus (Morgane PJ, Panskepp J, eds), pp 557– 620.
New York: Marcel Dekker.
Pardini AW, Nguyen HT, Figlewicz DP, Baskin DG, Williams DL, Kim F,
Schwartz MW (2006) Distribution of insulin receptor substrate-2 in
brain areas involved in energy homeostasis. Brain Res 1112:169 –178.
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